Betaliq

Betaliq, Inc. is a clinical-stage pharmaceutical company established in 2018 as a strategic collaboration between the German specialty pharmaceutical firm Novaliq GmbH and BLP Management Group, LLC. Located in Tampa, Florida, the company is focused on developing and commercializing treatments for glaucoma, a leading cause of irreversible blindness that affects over 80 million people globally. The company was founded to leverage Novaliq's proprietary EyeSol® technology for the glaucoma market, with an initial Series A funding round of $8 million completed in 2019.

The company is led by CEO Barry Butler, a seasoned pharmaceutical executive with over 35 years of industry experience. His career includes roles as Global Category Leader for Pharmaceuticals at Bausch & Lomb and founder and CEO of Sirion Therapeutics. Butler formed BLP Management Group after his time at Point Guard Partners, a consultancy for the ophthalmic industry, bringing extensive experience in drug development to Betaliq's operations.

Betaliq's business model centers on the clinical development of ophthalmic beta-blockers using the EyeSol® drug delivery platform, for which it holds exclusive rights for glaucoma therapies. This technology is the first water-free eye drop platform, offering significant advantages over traditional water-based drops. Its key features include a much smaller drop size—approximately one-quarter of the size of standard drops—which can reduce systemic absorption and associated side effects. The EyeSol® vehicle also provides for a longer residency time on the ocular surface, improved tissue penetration, and the elimination of preservatives like benzalkonium chloride, which can cause ocular irritation.

The company's product pipeline is aimed at addressing unmet needs in the glaucoma market. Its lead candidate, BTQ1902, is a preservative-free timolol suspension formulated with EyeSol®. Following positive Phase 2a clinical trial data, Betaliq is advancing BTQ1902 towards Phase 3 trials. Another product, BTQ1901, is an EyeSol-based formulation of a selective beta-blocker not previously used for glaucoma. The company's strategy involves developing a portfolio of glaucoma therapies and expanding into other areas of ophthalmology through partnerships. Recently, in March 2025, Betaliq and Eyenovia, Inc. signed a non-binding letter of intent for a potential reverse merger to combine Betaliq's EyeSol® technology with Eyenovia's Optejet® dispensing platform.

Keywords: glaucoma treatment, ophthalmic pharmaceuticals, clinical-stage company, EyeSol technology, water-free eye drops, beta-blockers, timolol, intraocular pressure, ocular hypertension, drug delivery platform, Barry Butler, Novaliq, BLP Management Group, BTQ1902, preservative-free, topical ophthalmic therapies, vision care, eye care, pharmaceutical development, reverse merger, Eyenovia